PROTON RADIATION THERAPY RESEARCH

质子放射治疗研究

• 批准号: 3092951
• 负责人: JAY Steven LOEFFLER
• 金额: $ 297.03万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-08-01 至 1995-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3092951
• 关键词: human therapy evaluation; neoplasm /cancer radiation therapy; particle accelerators; proton beam; radiation therapy dosage; ultrasonography

The superior dose distributions which can be achieved by proton beams will be evaluated for their efficacy in clinical radiation therapy. The basis for interest is that for some anatomic sites, the proton treatment volumes will be smaller and conform more closely to the target volumes than is possible with photon beams. As a consequence, the dose to the target can be increased and hence also the tumor control probability. Since there will be less non-target normal tissues being irradiated, we anticipate that the frequency and severity of normal tissue damage will be reduced. In project 1 we employ Phase III and Phase II trials to test these dose distributions against diseases at several sites. In project 2 we will use the patient database acquired in project 1 to analyze the dose response relationships for normal tissues and tumors. Project 3 makes the other two projects possible; new treatment planning, delivery, and quality control measures will be developed and implemented to allow more efficient and even more precise treatments to be delivered. Clinical Trials (project 1) Existing clinical trials of proton beams will be continued and new trials begun. Existing trials are for treatment of 1) chordomas and chondrosarcomas of the base of skull and cervical spine and 2) stage T3-T4 carcinoma of the prostate. Phase II and III trials will be undertaken for: 1) glioblastoma multiform (90 CGE; 1.8 CGE bid) 2) T3 glottis (80 CGE, 1.6 CGE bid), 3) sarcomas involving S1-S2 (about 75 CGE qd), 4) uveal melanoma (70 vs 50 CGE) 5) benign recurrent meningioma (59.4 CGE vs 50.4 Gy), and 6) early rectal cancer (66.6 CGE vs 59.4 Gy). Other sites are under consideration. Clinical Investigations (project 2) Evaluations and analyses will be performed on the patient data from project 1 yielding quantitative information on: the dose-response of fully or partially irradiated normal tissues; and the tumor control under conditions of non-uniform irradiation of the target volume. In addition, comparative treatment planning studies will be performed which will suggest techniques for, and the benefit from, proton beam therapy at several sites and provide comparisons of various technologies for improving dose distributions. Physics (project 3) This project has two goals: 1) to develop techniques for better proton beam treatments through improvements in beam quality, treatment planning, treatment techniques and 2) to increase the speed and efficiency of proton beam therapy. When these goals are realized, tumor/sites will have been identified for which improved proton therapy leads to higher frequencies of tumor control and/or reduced morbidity.

质子束可以实现的优异剂量分布将 评估其在临床放射治疗中的疗效。 基础 有趣的是，对于某些解剖部位，质子治疗量 将会比原来更小并且更符合目标体积 可以通过光子束实现。 因此，目标剂量可以 增加，因此肿瘤控制的可能性也增加。 自从那里 受到照射的非目标正常组织将会减少，我们预计 正常组织损伤的频率和严重程度将会降低。 在 项目 1 我们采用 III 期和 II 期试验来测试这些剂量 在几个地点分发针对疾病的药物。 在项目2中我们将使用 项目 1 中获取的用于分析剂量反应的患者数据库 正常组织和肿瘤的关系。 项目 3 使另外两个 可能的项目；新的治疗计划、实施和质量控制 将制定和实施措施，以提高效率和均匀度 提供更精确的治疗。 临床试验（项目 1） 现有的质子束临床试验将 继续进行并开始新的试验。 现有试验用于治疗 1) 颅底和颈椎的脊索瘤和软骨肉瘤 2)T3-T4期前列腺癌。 II 期和 III 期试验将进行 进行以下项目：1) 多形性胶质母细胞瘤（90 CGE；1.8 CGE 出价）2) T3 声门（80 CGE，1.6 CGE 出价），3）涉及 S1-S2 的肉瘤（约 75 CGE qd), 4) 葡萄膜黑色素瘤 (70 vs 50 CGE) 5) 良性复发性脑膜瘤 (59.4 CGE 对比 50.4 Gy)，以及 6) 早期直肠癌（66.6 CGE 对比 59.4 Gy）。 其他 选址正在考虑之中。 临床研究（项目 2） 评估和分析将 对项目 1 中的患者数据进行定量分析 信息：完全或部分受辐射的正常剂量反应 纸巾；以及非均匀照射条件下的肿瘤控制 的目标体积。 此外，比较治疗计划研究 将进行这将建议技术和好处， 在多个部位进行质子束治疗，并提供各种治疗方法的比较 改善剂量分布的技术。 物理（项目 3） 该项目有两个目标：1）开发技术 通过提高束质量来获得更好的质子束治疗， 治疗计划、治疗技术和 2) 提高速度和 质子束治疗的效率。 当这些目标实现时，肿瘤/部位将被识别出来 改进的质子治疗可以提高肿瘤控制的频率 和/或降低发病率。